Email this article Multiple sclerosis progression and galanin receptor GALR2: is there evidence for a link?
- Authors: Lioudyno V.I.1, Ilves A.G.2, Bisaga G.N.3, Abdurasulova I.N.1
-
Affiliations:
- Institute of Experimental Medicine
- N.P. Bechtereva Institute of the Human Brain
- Almazov National Medical Research Center
- Issue: Vol 21, No 2 (2021)
- Pages: 107-111
- Section: Clinical research
- URL: https://journals.rcsi.science/MAJ/article/view/75854
- DOI: https://doi.org/10.17816/MAJ75854
- ID: 75854
Cite item
Open Access
Access granted
Subscription Access
Abstract
BACKGROUND: Given the recently proposed role of the rare galanin receptor-2 (GALR2) gene’s missense mutation (SNP rs61745847) in the etiology of MS, we genotyped rs61745847 in a group of MS patients that was enriched with an unfavorable disease course cases.
MATERIALS AND METHODS: Our study cohort consisted of 100 MS patients selected based on their progressive course, high disease progression rate and pediatric onset. To determine the nucleotide sequence of GALR2 gene fragment, surrounding the rs61745847 area, Sanger sequencing of PCR amplicons was performed.
RESULTS: No homozygous rs61745847 carrier was found in our cohort, and the region of exon 2 surrounding rs61745847 completely coincided with the reference sequence (Gene Bank NC_000017.11). In agreement with previously published data on Canadian and Brazilian populations of patients, our study of a Russian cohort confirmed the rarity of the rs61745847 variant, including among patients with rapidly progressive MS.
CONCLUSIONS: Thus, although structural changes in the GALR2 gene associated with rs61745847 may play a significant role in individual patients carrying this rare mutation, it is unlikely that such changes determine an unfavorable disease course of MS in general.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Victoria I. Lioudyno
Institute of Experimental Medicine
Author for correspondence.
Email: vlioudyno@mail.ru
ORCID iD: 0000-0002-1449-7754
PhD (Biology), Senior Research Associate, Pavlov Department of Physiology
Russian Federation, Saint PetersburgAlexandr G. Ilves
N.P. Bechtereva Institute of the Human Brain
Email: ailves@hotmail.com
PhD (Medicine), Senior Research Associate, Laboratory of Neuroimmunology
Russian Federation, Saint PetersburgGennadij N. Bisaga
Almazov National Medical Research Center
Email: bisaga@yandex.ru
MD, Professor, Department of Neurology and Psychiatry, Institute of Medical Education
Russian Federation, Saint PetersburgIrina N. Abdurasulova
Institute of Experimental Medicine
Email: i_abdurasulova@mail.ru
PhD (Biology), Head of Laboratory, Pavlov Department of Physiology
Russian Federation, Saint PetersburgReferences
- Garcia-Rosa S, Trivella DB, Marques VD, et al. A non-functional galanin receptor-2 in a multiple sclerosis patient. Pharmacogenomics J. 2019;19(1):72–82. doi: 10.1038/s41397-018-0032-6
- Encarnacion M, Bernales CQ, Traboulsee AL, et al. Analysis of galanin receptor GALR2 in multiple sclerosis. Pharmacogenomics J. 2019;19(6):499–500. doi: 10.1038/s41397-019-0100-6
- Abbosh C, Lawkowski A, Zaben M, Gray WP, et al. GalR2/3 mediates proliferative and trophic effects of galanin on postnatal hippocampal precursors. J Neurochem. 2011;117(3):425–436. doi: 10.1111/j.1471-4159.2011.07204.x
- Wraith DC, Pope R, Butzkueven H, et al. A role for galanin in human and experimental inflammatory demyelination. Proc Natl Acad Sci USA. 2009;106(36):15466–15471. doi: 10.1073/pnas.0903360106
- Gresle MM, Butzkueven H, Perreau VM, et al. Galanin is an autocrine myelin and oligodendrocyte trophic signal induced by leukemia inhibitory factor. Glia. 2015;63(6):1005–1020. doi: 10.1002/glia.22798
- Lyubetska H, Zhang L, Kong J, Vrontakis M. An elevated level of circulating galanin promotes developmental expression of myelin basic protein in the mouse brain. Neuroscience. 2015;284:581–589. doi: 10.1016/j.neuroscience.2014.10.031
- Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302. doi: 10.1002/ana.22366
- Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi: 10.1016/S1474-4422(17)30470-2
- Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005;64(7):1144–1151. doi: 10.1212/01.WNL.0000156155.19270.F8
Supplementary files
